DPP4 and fatty liver disease: On the contrary, sitagliptin, an oral dipeptidyl peptidase-4 (DPP4) inhibitor, in a recent RCT did not significantly reduce liver steatosis in prediabetic or diabetic patients with NAFLD [244].